Trimel BioPharma SRL announced the sale of acquisition rights to NATESTOTM testosterone nasal spray to Endo International plc in December 2014. (PRNewsWire) NATESTOTM is the first commercially available testosterone nasal gel for replacement therapy in adult men suffering from low testosterone with U.S. Food and Drug Administration (F.D.A.) approval received in May 2014. NATESTOTM has received noticeable reviews in multiple clinical studies, earning a weight price tag of $25M plus additional payment from Endo International plc.

At the time of the announced acquisition, Rajiv De Silva, President and CEO of Endo had this to say, “We are pleased to acquire the rights to Natesto to further enhance our branded pharmaceutical portfolio and look forward to leveraging our commercial expertise in the areas of men’s health and urology to support this highly differentiated product.”

On March 16th, 2015 Endo International announced the new commercial availability of NATESTOTM through its subsidiary Endo Pharmaceuticals. (NASDAQ) Its unique intranasal application reduces the risk of transference and is specifically targeted for treatment in adult men with primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism (congenital or acquired). Dosage recommendation is 11 mg of testosterone (two 5.5 mg-metered pumps per nostril) three times daily for a full daily dosage of 33 mg. (Endo) NATESTOTM is not recommended for men with carcinoma of the breast area or men with known or suspected prostate cancer.

NATESTOTM is just one of many available products designed to help aging men with low testosterone regain the fullest life possible. We’ve written a free ebook, available for instant download to help you learn more about low testosterone. It can be used as a guide for diagnosing and monitoring low T treatment. Find out if you have hormone imbalance or low testosterone and then get the proper treatment. This medically referenced guide is available right now and written in language easy to understand.